These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab. Choi JN Semin Cutan Med Surg; 2014 Mar; 33(1):40-8. PubMed ID: 25037257 [TBL] [Abstract][Full Text] [Related]
10. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. Hwang SJ; Carlos G; Wakade D; Byth K; Kong BY; Chou S; Carlino MS; Kefford R; Fernandez-Penas P J Am Acad Dermatol; 2016 Mar; 74(3):455-61.e1. PubMed ID: 26793994 [TBL] [Abstract][Full Text] [Related]
11. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge]. Capovilla M Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719 [TBL] [Abstract][Full Text] [Related]
12. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Yun S; Vincelette ND; Green MR; Wahner Hendrickson AE; Abraham I Cancer Med; 2016 Jul; 5(7):1481-91. PubMed ID: 27167347 [TBL] [Abstract][Full Text] [Related]
13. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks. Anforth R; Carlos G; Clements A; Kefford R; Fernandez-Peñas P Br J Dermatol; 2015 Jan; 172(1):239-43. PubMed ID: 25040674 [TBL] [Abstract][Full Text] [Related]
14. [Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors]. Gutzmer R; Hassel JC; Kähler KC; Loquai C; Mössner R; Ugurel S; Zimmer L; der das Ado FK Hautarzt; 2014 Jul; 65(7):582-9. PubMed ID: 24903029 [TBL] [Abstract][Full Text] [Related]
15. [Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology]. Sibaud V; Delord JP; Chevreau C; Gangloff D; Garrido-Stowhas I Ann Chir Plast Esthet; 2012 Apr; 57(2):106-13. PubMed ID: 22425393 [TBL] [Abstract][Full Text] [Related]
16. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations. Sinha R; Larkin J; Gore M; Fearfield L Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403 [TBL] [Abstract][Full Text] [Related]
17. Cutaneous toxicities of new treatments for melanoma. Boada A; Carrera C; Segura S; Collgros H; Pasquali P; Bodet D; Puig S; Malvehy J Clin Transl Oncol; 2018 Nov; 20(11):1373-1384. PubMed ID: 29799097 [TBL] [Abstract][Full Text] [Related]
18. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767 [TBL] [Abstract][Full Text] [Related]
20. Advances in the Immunobiological Therapies for Advanced Melanoma. Pérez Gago MC; Saavedra Santa Gadea O; de la Cruz-Merino L Actas Dermosifiliogr; 2017 Oct; 108(8):721-728. PubMed ID: 28388991 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]